Introduction
The prognosis of patients with metastatic gastric cancer is extremely poor. The median survival time of these patients is approximately 3 to 4 months with the best supportive care [1] [2] [3] . Several randomized phase III studies comparing best supportive care and com bination chemotherapy have revealed that the overall survival was signifi cantly prolonged in patients who received chemotherapy, suggesting that chemotherapy should be recommended for these patients [1] [2] [3] . New drugs, such as S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) [4, 5] , paclitaxel [6, 7] , docetaxel [8, 9] and irinotecan hydrochloride (CPT-11) [10] , have been developed and several combination regimens have been tested in Japan.
Docetaxel, a taxane, is an antimicrotubule agent that enhances the polymerization of tubulin into stable microtubules and inhibits microtubule depolymerization [11] . It has shown promising activity in gastric cancer both as a single agent and in combination with other agents. TAX 325, a recent phase III study, demonstrated that overall survival with triple-agent chemotherapy using docetaxel, 5-fl uorouracil (5-FU), and cisplatin was signifi cantly superior to that of 5-FU and cisplatin [12] . However, this triplet chemotherapy had severe toxicity. Moreover, 5-FU and cisplatin need the patients to be hospitalized for administration. Oral 5-FU analogues and prodrugs are attractive alternative agents for combination with docetaxel.
Doxifl uridine is an oral fl uoropyrimidine that is metabolized to 5-FU by thymidine phosphorylase, which is mainly activated in the tumor tissue [13] . Doxifl uridine is also known as an intermediate metabolite in the conversion of capecitabine to 5-FU [14] . Capecitabine has been widely used all over the world except in Japan, where it has not been approved for gastric cancer. Doxifl uridine is less toxic than systemically administered 5-FU [14] , as the conversion of doxifl uridine into 5-FU takes place mainly in the tumor tissue [15] . The most prominent toxicity of doxifl uridine is reportedly diarrhea [14] . Doxifl uridine is active against gastric cancer both as a single agent and in combination with other drugs.
Thus, docetaxel and doxifl uridine have different mechanisms of antitumor activity and they have different toxicity profi les. The fact that the dose-limiting toxicities of the two drugs did not overlap seemed to be an advantage when compared with combinations such as docetaxel and S-1. Moreover, taxanes have been shown to upregulate the enzyme activity of thymidine phosphorylase in a human colon cancer xenograft model, and thereby the tumor sensitivity to doxifl uridine or capecitabine may be enhanced [16] . Several combinations of taxanes with these two oral fl uoropyrimidines have been developed and tested in solid tumors, among which the present combination was investigated in patients with breast cancer and proved to be active and well tolerated [17] . These fi ndings prompted the authors to conduct a phase I study of a combination of doxifl uridine, administered for 14 consecutive days every 3 weeks, and docetaxel, given on day 8, in gastric cancer patients [18] . The recommended dose was determined as docetaxel 50 mg/m 2 and doxifl uridine 533.3 mg/m 2 per day [18] . Based on these reports, we initiated a phase II study to further evaluate the effi cacy and toxicity profi le of this regimen in patients with metastatic gastric cancer. As docetaxel is considered to be equally active regardless of previous chemotherapy, we allowed the registration of pretreated patients, provided that the previous chemotherapy of up to two regimens had not contained taxanes.
Patients and methods

Selection of patients
The eligibility criteria were: histologically or cytologically confi rmed unresectable or recurrent gastric adenocarcinoma; at least one measurable lesion or a primary tumor; possible oral intake; less than two prior regimens which did not include a taxane, completed at least 2 weeks before entry; age range from 20 to 80 years; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; an estimated survival of at least 2 months; suffi cient organ function (white blood cell [WBC] count ≥3000/mm 3 and ≤12 000/mm 3 , neutrophil count ≥1500/mm 3 , platelet count ≥100 000/mm 3 , GOT ≤100 U/l and GPT ≤100 U/l, total bilirubin <1.5 mg/dl, creatinine <1.5 mg/dl, normal ECG), and the patient's written informed consent. The exclusion criteria were a past history of allergic reactions to the medications, a severe medical condition, a symptomatic infectious disease, peripheral neuropathy or edema of grade 2 or greater, interstitial pneumonitis or lung fi brosis, symptomatic pleural effusion or ascites, clinically apparent brain metastasis, synchronous neoplasms which required treatment, and women who were pregnant or lactating.
Treatment schedule
One cycle consisted of 3 weeks. Doxifl uridine 533.3 mg/ m 2 per day was given orally twice daily for 2 weeks followed by a drug-free interval of 1 week. Docetaxel 50 mg/m 2 was administered as at least a 1-h infusion on day 8. Dexamethasone 8 mg was infused 1 h before docetaxel administration to reduce the risk of hypersensitivity reaction. Granulocyte colony-stimulating factor was permitted if a patient developed grade 4 neutropenia or febrile neutropenia. Primary prophylaxis was not allowed. Treatment was continued until disease progression, unacceptable toxicity, patient refusal, or the physician's decision to stop treatment.
Toxicity was graded according to the National Cancer Institute common toxicity criteria version 2.0. At the initiation of each course, if the patient had a WBC count of 3000/mm 3 or lower, neutrophil count of 1500/mm 3 or lower, platelet count of 100 000/mm 3 or lower, total bilirubin of 2.0 mg/dl or higher, creatinine of 1.5 mg/dl or higher, GOT and GPT of 100 U/l or higher, alkaline phosphatase of grade 1 or higher, or nonhematological toxicities of grade 3 or higher, the drug administration was postponed until recovery from these adverse events. If the adverse events persisted for an additional 2 weeks, then the chemotherapy was stopped. If the patient had a history of postponement of chemotherapy due to these adverse events, or had neutropenia of grade 4, febrile neutropenia, a platelet count of 100 000/mm 3 or lower, or nonhematological toxicities of grade 3 or higher other than diarrhea, nausea, vomiting, appetite loss, fatigue, or hypersensitivity, then the next doses of doxifl uridine and docetaxel were reduced to 400 mg/m 2 and 40 mg/m 2 , respectively. If the patient had diarrhea of grade 3 or higher, then the next dose of doxifl uridine was reduced to 400 mg/m 2 .
Statistical considerations
The primary endpoint was the response rate. The clinical response was evaluated once every cycle by the response evaluation criteria in solid tumors (RECIST), with a central review by two extramural physicians. A primary analysis was conducted to assess whether the lower limit of the 95% confi dence interval (CI) of the response rate was greater than 7%. We assumed a response rate of 20% and a threshold setting of 7%. With a statistical power of 80%, a total of 39 patients were required. Considering the possible inclusion of ineligible patients, we planned to enroll 41 patients. The secondary endpoints were overall survival, progressionfree survival, and toxicities. The overall survival was defi ned as the time from the date of registration to death due to any cause. Progression-free survival was defi ned as the time from registration until tumor progression or any cause of death, and was fi nally determined by a meeting of investigators and the radiological review committee. Toxicities were evaluated once every week. Eight institutions constituting the Gastric Cancer Synergistic Effect Chemotherapy Group participated in the trial, which was approved by the institutional review boards of all institutions.
Results
Between June 2004 and December 2006, a total of 41 patients were enrolled in this study. One patient was judged as ineligible, because this patient did not fulfi ll the criteria for initiating the fi rst course of chemotherapy, due to a decrease in the WBC count after the enrollment. The characteristics of the 40 eligible patients are summarized in Table 1 . One patient was not assessable, but was included in the intention-to-treat analysis and kept in the denominator of the response rate. The details of prior chemotherapy are shown in Table 2 . Only 3 patients were chemotherapy-naïve, while the other 37 patients (93%) had received prior chemotherapy. When "refractory tumors" were defi ned as: (1) progressive disease according to RECIST during therapeutic chemotherapy or (2) tumors that had recurred within 6 months after completing the perioperative chemotherapy, 32 patients had refractory tumors. Of these 32 patients, 31 had S1-refractory tumors. The patients completed a median of 3 cycles of the treatment (range, 1-12). The response rate is shown in Table 3 . Seven of the 40 patients showed a partial response, with an overall response rate of 17.5% (95% CI, 5.2% to 29.8%). Fourteen patients showed stable disease. When the 3 chemotherapy-naïve patients were excluded, the response rate was 18.9% (95% CI, 5.7% to 32.2%; Table 3 ). The response rate was 18.8% in the 32 patients with refractory tumors and 19.4% in the 31 patients with S1-refractory tumors.
All eligible patients were followed up for more than 12 months after the enrollment. The median follow-up period was 23.2 months. At the time of analysis, 32 patients had already died. The median overall survival and the median progression-free survival in all 40 patients were 12.7 months and 2.6 months, respectively ( Figs. 1 and 2) , and 14.0 months and 2.6 months, respectively, in the 32 patients with refractory tumors (Figs. 3  and 4) .
The toxicities are summarized in Table 4 . The most common grade 3 or 4 hematological toxicity was neutropenia (52.5%). Febrile neutropenia was observed in 7.5%. On the other hand, grade 3 or more nonhematological toxicities were rare, including fever (5%), anorexia (5%), stomatitis (2.5%), and edema (2.5%). No treatment-related death was observed. 
Discussion
A combination of either capecitabine or doxifl uridine with the taxanes that upregulate thymidine phosphorylase activity [16] is theoretically promising, and has been evaluated with various types of cancer. Among these two, only doxifl uridine is available for the treatment of gastric cancer in Japan. As a combination of this drug with paclitaxel has already been explored [19] , the authors chose to explore a combination with docetaxel. The response rate of this combination chemotherapy was lower than expected, at 17.5%, and our statistical hypothesis in this phase II study was not met. One of the reasons could be that most patients were not chemonaive in the study population. While our study was accruing patients, two other important phase III trials to fi nd the standard fi rst-line chemotherapy for gastric cancer were taking place, and one of the candidate agents in both of the trials was S-1. This could partially explain why only three patients in the present study were chemotherapy-naïve. Anyhow, the activity of the present regimen in the fi rst-line setting could not be evaluated. Among the 40 patients who were enrolled in this study, 35 had received one prior regimen and 32 had refractory tumors. Thus, the results observed in this study should be interpreted essentially as those of a phase II trial in the second-line setting, which generally results in lower response rates.
Since S1 plus cisplatin was established as the standard fi rst-line chemotherapy in Japan, based on several phase III trials [20] [21] [22] , attention had been focused clinically on the development of second-line chemotherapy. In the present study, the response rate was 18.8% in the 32 patients who received the trial regimen as secondor third-line chemotherapy. In particular, the response rate was 19.4% for the patients with S1-refractory tumors. Several investigators have reported on the efficacy of second-line chemotherapy for gastric cancer using various combinations of docetaxel with another anticancer agent. Response rates in these combinations ranged from 10.5% to 29% [23] [24] [25] [26] [27] [28] . Thus, our result was equivalent to those in most of these studies.
The response rate is generally expected to be higher with combination therapy than with single-agent treatment. In fact, the response rates were reported to be 21.7% and 21.9% among pretreated patients in two independent phase II studies of docetaxel as a single agent [8, 9] . The response rate of the present combination of docetaxel and doxifl uridine was found not to be superior to the response rate of single-agent therapy, and this could be considered as a drawback. Surprisingly, however, the toxicity profi le of the present combination was milder than that of the monotherapy. The predominant grade 3 or more adverse events affected neutrophils in 52.5%, leucocytes in 17.5%, and hemoglobin in 12.5%. Febrile neutropenia was observed in 7.5%. The major known toxicities of docetaxel are bone marrow suppression, especially leukocytopenia, neutropenia, and febrile neutropenia [8, 9] . These were also dose-limiting toxicities in most regimens containing docetaxel. All hematological toxicities in the present trial were not so frequent and manageable. On the other hand, compared with results in the present trial, bone marrow suppression was reportedly more severe and more frequently observed with other regimens containing docetaxel [23] [24] [25] [26] [27] . In the present regimen, docetaxel at a dose of 50 mg/m 2 was given every 3 weeks, but in other regimens it was given at a dose of 60 mg/m 2 to 75 mg/m 2 every 3 weeks [23-25, 27, 28] . Thus, the lower dose intensity in the present trial may have contributed to the severity and the incidence of myelosuppression observed in this study. In addition, nonhematological toxicities were rare in the present study. Grade 3 or more gastrointestinal toxicities were seen in fewer than 5%. Neither hand-foot syndrome nor grade 3 or more diarrhea occurred. In a phase II study using doxifl uridine, hand-foot syndrome was not observed, but diarrhea occurred in 26.3% [15] . Rosati et al. [27] reported that hand-foot syndrome of grade 3 or more was observed in 7% and grade 3 diarrhea was observed in 11% with docetaxel and capecitabine as second-line chemotherapy for metastatic gastric cancer. Again, the relatively low dose intensity of doxifl uridine in our study may have contributed to the severity and the incidence of diarrhea observed in this study.
In contrast to the response rate, the median overall survival time in the present study was longer than expected from the study population: 12.7 months in all 40 patients and 14.0 months in the 32 patients with refractory tumors. The median overall survival time in the present study (>12 months) was similar to that seen with fi rst-line chemotherapy in several phase III studies.
In the phase III trial of S-1 plus cisplatin versus S-1 alone for the fi rst-line treatment of advanced gastric cancer (SPIRITS), the median overall survival time was 13.0 months with S1 and cisplatin and 12.0 months with S1 alone [21] . In the Japanese Clinical Oncology Group (JCOG) 9912 trial, the median overall survival time was 10.8 months with 5-FU, 12.3 months with CPT-11 and cisplatin, and 11.4 months with S1 [20] . In several previous reports of second-line chemotherapy, the median overall survival time ranged from 4 to 9 months [25] [26] [27] [28] . In contrast to the overall survival time in the present study, the median progression-free survival was unimpressive, at 2.6 months, meaning that the patients generally lived long after disease progression. This may have been due to the successful introduction of effective third-line chemotherapy, but detailed information regarding this issue was not looked at in this trial.
To conclude, although the effi cacy of the present doxifl uridine/docetaxel combination in the fi rst-line setting was not evaluated, this combination could be feasible as second-line chemotherapy. Although the dose intensities of docetaxel and doxifl uridine were relatively low, the response rate and progression-free survival were moderate and the overall survival was excellent. The mild toxicity profi le of the present regimen may have increased treatment compliance, and this may have made it easier for the patients to accept further lines of therapy when the disease failed to respond to this combination; these factors may have been causes of the prolonged overall survival.
